Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOPSKIN: Validation of bioprinted autologous skin substitute
NCT04925323Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jan 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial of Poieskin in wound, sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: bioprinted dermo epidermal substitute sterility assessment at 24 months, Population Doubling Rate of keratinocytes at 24 months and 1 more. Status: unknown.
02
Drugs
Poieskin
03
Conditions
wound
Beyond the preview
Go deeper on NCT04925323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925323.